Important Information About EXKIVITY^® (mobocertinib)

On October 2, 2023, Takeda announced the initiation of a voluntary withdrawal of EXKIVITY (mobocertinib) 40 mg capsules, for oral use, from the market in the United States (U.S.). This decision was made in consultation with the US Food and Drug Administration (FDA).

EXKIVITY remains available to prescribe while Takeda works with the FDA on withdrawal timing. Takeda will provide updates when and as appropriate.

Takeda is committed to ensuring that patients receiving EXKIVITY can maintain access when EXKIVITY is withdrawn.

For additional questions, please contact Takeda at 844-662-8532 or globaloncologymedinfo@takeda.com.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc.
at 1-844-217-6468 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.